Quality of life should be the primary outcome for disease-modifying therapy trials in MS-Yes.

Mult Scler

Kessler Foundation, West Orange, NJ, USA/Department of Physical Medicine and Rehabilitation, New Jersey Medical School, Rutgers University, Newark, NJ, USA.

Published: August 2023

Download full-text PDF

Source
http://dx.doi.org/10.1177/13524585231182705DOI Listing

Publication Analysis

Top Keywords

quality life
4
life primary
4
primary outcome
4
outcome disease-modifying
4
disease-modifying therapy
4
therapy trials
4
trials ms-yes
4
quality
1
primary
1
outcome
1

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!